Meissner, Barbara http://orcid.org/0000-0002-5242-5559
Lang, Peter http://orcid.org/0000-0001-7737-2142
Bader, Peter http://orcid.org/0000-0003-4554-0265
Hoenig, Manfred http://orcid.org/0000-0001-9165-1690
Müller, Ingo http://orcid.org/0000-0002-7477-6632
Meisel, Roland http://orcid.org/0000-0001-5230-0628
Greil, Johann http://orcid.org/0000-0003-1821-1183
Sauer, Martin G. http://orcid.org/0009-0007-2151-8342
Metzler, Markus
Corbacioglu, Selim
Burkhardt, Birgit http://orcid.org/0000-0002-1151-829X
Wölfl, Matthias http://orcid.org/0000-0002-9608-3482
Strahm, Brigitte http://orcid.org/0000-0002-6086-130X
Kafa, Kinan http://orcid.org/0009-0009-3359-2894
Basu, Oliver
Lode, Holger N.
Gruhn, Bernd http://orcid.org/0000-0003-1862-0075
Cario, Holger http://orcid.org/0000-0002-6923-488X
Ozga, Ann-Kathrin
Zimmermann, Martin http://orcid.org/0000-0002-0365-3512
Jarisch, Andrea http://orcid.org/0000-0003-1639-2697
Beier, Rita http://orcid.org/0000-0002-7568-8749
Funding for this research was provided by:
Deutsche Kinderkrebsstiftung (DKS 2021.07, DKS 2021.07)
Article History
Received: 5 June 2023
Revised: 16 January 2024
Accepted: 18 January 2024
First Online: 7 February 2024
Competing interests
: PB declares research grants from Neovii, Riemser, Medac, and Bristol Myer Squibb (BMS) (to Institution); membership in advisory boards for Novartis, Cellgene, Amgen, Medac, Servier (personal and to Institution); received speaker fees from Miltenyi, Jazz, Riemser, Novartis, and Amgen (to institution); and declares a patent and royalties from Medac. RM reports research support from and cooperation with Jazz, Miltenyi Biotech, Neovii, Novartis, Celgene BMS, Gilead/KITE, CRISPR Therapeutics and Vertex Pharmaceuticals. MW received Honoria from Amgen Research, Munich, Germany. BG received honoria from Amgen GmbH, EUSA Pharma GmbH, medac GmbH, Novartis Pharma GmbH; and reports membership on an entity’s Board of Directors or advisory committees for Amgen GmbH, EUSA Pharma GmbH. HC received consultancy fees and honoraria from Novartis, GBT (Pfizer), Vertex, Bluebird Bio, Agios, BMS (Celgene) and Chiesi. AJ declares speakers fees from Novartis and advisory board participation with Bluebird Bio and Novartis. RB received speaker’s fees from Medac. The remaining authors declare no competing financial interests.